170392 ⎘
Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates; Assays involving proteins of known structure or function as defined in the subgroups; Details Cyclin; Prad 1
USE OF CYCLIN E1 STATUS AS A PREDICTIVE BIOMARKER FOR TREATING CANCER WITH WEE1 INHIBITORS
#2CYCLIN-DEPENDENT KINASE 2 INHIBITORS FOR MEDICAL TREATMENT
#3WEE1 INHIBITORS AND METHODS FOR TREATING CANCER
#4MOLECULAR ANALYSIS OF EXTRACELLULAR VESICLES (EVs) FOR THE PREDICTION AND MONITORING OF DRUG RESISTANCE IN CANCER
#5Cyclin G1 inhibitors and related methods of treating cancer
#6A METHOD FOR SCREENING A THERAPEUTIC AGENT FOR CANCER USING BINDING INHIBITOR OF CYCLIN-DEPENDENT KINASE 1 (CDK1)-CYCLIN B1 AND RETINOIC ACID RECEPTOR RESPONDER 1 (RARRES1) GENE KNOCKOUT ANIMAL MODEL
#7METHODS, KITS, AND SYSTEMS FOR SCORING THE IMMUNE RESPONSE TO CANCER
#8BIOMARKERS FOR UROTHELIAL CARCINOMA AND APPLICATIONS THEREOF
#9Prediction of response to immune-modulatory therapies
#10Proteomic And Genomic Analysis For Colon Cancer Prognosis
#11Cyclin G1 inhibitors and related methods of treating cancer
#12BIOMARKERS ASSOCIATED WITH CDK INHIBITORS
#13CDK8-CDK19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer
#14Methods, kits, and systems for scoring the immune response to cancer
#15Methods And Marker Combinations For Screening For Predisposition To Lung Cancer
#16Antisense RNA for treating cancer and inhibition of metastasis and vectors for antisense sequestration
#17Methods and Compositions for the Diagnosis of a Thyroid Condition
#18BIOMARKERS ASSOCIATED WITH CDK INHIBITORS
#19Diagnostic Markers of Indolent Prostate Cancer
#20Isolated cardiac stem cells and methods of their use
#21Methods to predict progression of Barrett's Esophagus to high grade dysplasia esophageal adenocarcinoma
#22Methods And Marker Combinations For Screening For Predisposition To Lung Cancer
#23HEMATOPOIETIC PROTECTION AGAINST CHEMOTHERAPEUTIC COMPOUNDS USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS
#24BIOMARKERS FOR MONITORING THE TREATMENT BY QUINAZOLINONE COMPOUNDS
#25Novel tumor marker determination
#26CENTROSOME AMPLIFICATION AS A BIOSENSOR FOR DNA DAMAGE
#27Detection of uterine leiomyosarcoma using LMP2
#28Compositions and methods for treating and preventing heart tissue degeneration and uses thereof
#29Marks as modifiers of the p53 pathway and methods of use
#30Methods of treatment using a vector encoding p21/
#31Method for screening for compounds selectively interacting with RAD9
#32Antisense RNA for treating cancer and inhibition of metastasis and vectors for antisense sequestration
#33CDKI PATHWAY INHIBITORS AND USES THEREOF
#34Diagnostic panel of cancer antibodies and methods for use
#35BIOMARKERS FOR PREDICTING THE SENSITIVITY OF CELLS TO IMMUNOMODULATORY COMPOUNDS DURING TREATMENT OF NON-HODGKIN'S LYMPHOMA
#36SMIPs: Small molecule inhibitors of p27 depletion in cancers and other proliferative diseases
#37Methods For Determining Presence of Cancer by Analyzing the Expression of Cdk9 and/or Cyclin T1 in Lymphoid Tissue
#38Methods of treatment involving p21/CIP1
#39MARKs as Modifiers of the p53 Pathway and Methods of Use
#40Methods and marker combinations for screening for predisposition to lung cancer
#41Novel Cdk11 molecules and uses thereof
#42Identification of CDKI pathway inhibitors
#43Delta-tocotrienol treatment and prevention of pancreatic cancer
#44Methods of identifying an agent capable of interfering with Rad9 dephosphorylation
#45Method for judging feature of malignant tumor
#46Expression of cyclin G1 in tumors
#47Biomarkers of cyclin-dependent kinase modulation
#48Modulation of MAPK-mediated phosphorylation and/or FBXW8-mediated ubiquitinylation of cyclin D1 in modulation of cellular proliferation
#49Compositions and methods for treating and preventing heart tissue degeneration, and uses thereof
#50Cyclin groove inhibitors
#51Method for detecting carcinomas in a solubilized cervical body sample
#52LIMKs as modifiers of p53 pathway and methods of use
#53Compositions and methods for treating and preventing heart tissue degeneration and uses thereof
#54Gpcs as modifiers of the irrtk p21 pathways and methods of use
#55Methods for identifying therapeutic agents and for treating disease
#56CDK2/cyclin A crystals and uses thereof
#57PRMTs as modifiers of the p53 pathway and methods of use
#58Chds as modifiers of the p53 pathway and methods of use
#59Novel cell cycle genes required for mitotic entry
#60Dgks as modifiers of the p53 pathwha and methods of use